BACKGROUND: Respiratory syncytial virus (RSV) can cause severe respiratory disease in adult hematopoietic cell transplant (HCT) recipients. RSV subgroups A and B have evolved into multiple genotypes. We report on a recently described RSV genotype (ON1) in a cohort of adult HCT recipients in Texas. METHODS: Twenty adult HCT recipients were enrolled as a part of an efficacy trial of ribavirin therapy. RSV identification and genotyping was performed using molecular techniques. RSV-specific neutralizing antibody (NAb) responses were measured. RESULTS: ON1 genotype was detected in 3 of 6 patients in the 2011-2012 season and in 8 of 14 patients in 2012-2013 season. Other genotypes detected were NA1 and BA. NAb levels were low at enrollment. Eight of 9 patients who cleared the RSV infection within 2 weeks mounted a ≥4-fold NAb response, compared with 2 of 8 who shed the virus for >2 weeks. The clinical course of those infected with ON1 was comparable to the course for individuals infected with other genotypes. CONCLUSION: This is the first report of RSV ON1 genotype in the United States, and ON1 genotype was dominant genotype in adult HCT recipients. Interestingly, faster viral clearance was associated with a ≥4-fold NAb response, likely indicating a reconstituted immune system.
BACKGROUND:Respiratory syncytial virus (RSV) can cause severe respiratory disease in adult hematopoietic cell transplant (HCT) recipients. RSV subgroups A and B have evolved into multiple genotypes. We report on a recently described RSV genotype (ON1) in a cohort of adult HCT recipients in Texas. METHODS: Twenty adult HCT recipients were enrolled as a part of an efficacy trial of ribavirin therapy. RSV identification and genotyping was performed using molecular techniques. RSV-specific neutralizing antibody (NAb) responses were measured. RESULTS:ON1 genotype was detected in 3 of 6 patients in the 2011-2012 season and in 8 of 14 patients in 2012-2013 season. Other genotypes detected were NA1 and BA. NAb levels were low at enrollment. Eight of 9 patients who cleared the RSV infection within 2 weeks mounted a ≥4-fold NAb response, compared with 2 of 8 who shed the virus for >2 weeks. The clinical course of those infected with ON1 was comparable to the course for individuals infected with other genotypes. CONCLUSION: This is the first report of RSVON1 genotype in the United States, and ON1 genotype was dominant genotype in adult HCT recipients. Interestingly, faster viral clearance was associated with a ≥4-fold NAb response, likely indicating a reconstituted immune system.
Authors: Annefleur C Langedijk; Eline R Harding; Burak Konya; Bram Vrancken; Robert Jan Lebbink; Anouk Evers; Joukje Willemsen; Philippe Lemey; Louis J Bont Journal: Rev Med Virol Date: 2021-09-20 Impact factor: 11.043
Authors: Brittani N Blunck; Letisha Aideyan; Xunyan Ye; Vasanthi Avadhanula; Laura Ferlic-Stark; Lynn Zechiedrich; Brian E Gilbert; Pedro A Piedra Journal: Vaccine Date: 2021-01-26 Impact factor: 3.641
Authors: Venkata R Duvvuri; Andrea Granados; Paul Rosenfeld; Justin Bahl; Alireza Eshaghi; Jonathan B Gubbay Journal: Sci Rep Date: 2015-09-30 Impact factor: 4.379
Authors: Laurent Detalle; Thomas Stohr; Concepción Palomo; Pedro A Piedra; Brian E Gilbert; Vicente Mas; Andrena Millar; Ultan F Power; Catelijne Stortelers; Koen Allosery; José A Melero; Erik Depla Journal: Antimicrob Agents Chemother Date: 2015-10-05 Impact factor: 5.191
Authors: Anwar Ahmed; Shakir H Haider; Shama Parveen; Mohammed Arshad; Hytham A Alsenaidy; Alawi Omar Baaboud; Khalid Fahad Mobaireek; Muslim Mohammed AlSaadi; Abdulrahman M Alsenaidy; Wayne Sullender Journal: PLoS One Date: 2016-11-11 Impact factor: 3.240
Authors: Xunyan Ye; Obinna P Iwuchukwu; Vasanthi Avadhanula; Letisha O Aideyan; Trevor J McBride; David M Henke; Kirtida D Patel; Felipe-Andres Piedra; Laura S Angelo; Dimpy P Shah; Roy F Chemaly; Pedro A Piedra Journal: Viruses Date: 2021-05-26 Impact factor: 5.048